Valneva SE
 | |
| Company type | Societas Europaea |
|---|---|
| Euronext: VLA | |
| Industry | Biotechnology |
| Founded | 2013 |
| Fate | established through a merger of former Intercell and Vivalis SA |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Website | www |
Valneva SE is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA.[1]
It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013.
Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia)[2] and Dukoral, a vaccine against cholera (approved in Europe, America and Australia)[3]
Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa,[4] V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck),[5] and IC41, therapeutic vaccine against hepatitis C[6]
References
- ^ "Valneva SE company profile, wiener börse". Retrieved 2017-09-02.
- ^ "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency (EMA). 2009-06-05. Retrieved 2017-04-25.
- ^ "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency (EMA). 2009-04-30. Retrieved 2017-04-25.
- ^ "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
- ^ "Merck ends trial of Intercell's MRSA vaccine". Reuters. 2011-06-08. Retrieved 2017-04-25.
- ^ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.
External links
 | This French corporation or company article is a stub. You can help Wikipedia by expanding it. |
 | This article on an Austrian company is a stub. You can help Wikipedia by expanding it. |